Literature DB >> 10486693

Management strategies in unstable coronary artery disease--current problems and future directions. The UCAD Council.

F W Verheugt1, R C Becker, M E Bertrand, C Bode, J H Chesebro, J G Cleland, R Conti, W S Hillis, W Klein, A Maseri, A G Turpie, L Wallentin, D D Waters.   

Abstract

Unstable coronary artery disease continues to pose a major challenge to clinicians. The advent of new therapies, such as percutaneous transluminal coronary angioplasty, low-molecular-weight heparins, and glycoprotein IIb/IIIa inhibitors, provides new management options for this indication but also raises new questions with regard to optimal management. Prospective randomized trials with well-defined, long-term outcome measures and a means of identifying which patients will derive most benefit from each treatment, together with a means of rapid and clear dissemination of study results and implications, are required in order to advance the management of unstable coronary artery disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10486693      PMCID: PMC6655658          DOI: 10.1002/clc.4960220903

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  17 in total

1.  Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC)

Authors:  W Klein; A Buchwald; S E Hillis; S Monrad; G Sanz; A G Turpie; J van der Meer; E Olaisson; S Undeland; K Ludwig
Journal:  Circulation       Date:  1997-07-01       Impact factor: 29.690

2.  Aspirin, heparin, or both to treat acute unstable angina.

Authors:  P Théroux; H Ouimet; J McCans; J G Latour; P Joly; G Lévy; E Pelletier; M Juneau; J Stasiak; P deGuise
Journal:  N Engl J Med       Date:  1988-10-27       Impact factor: 91.245

3.  Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection. Fragmin in Unstable Coronary Artery Disease (FRISC) Study Group.

Authors:  B Lindahl; P Venge; L Wallentin
Journal:  J Am Coll Cardiol       Date:  1997-01       Impact factor: 24.094

4.  Predictors of risk in patients with unstable angina admitted to a district general hospital.

Authors:  J J Murphy; P A Connell; J R Hampton
Journal:  Br Heart J       Date:  1992-05

5.  Diagnosing and managing unstable angina. Agency for Health Care Policy and Research.

Authors:  E Braunwald; R H Jones; D B Mark; J Brown; L Brown; M D Cheitlin; C A Concannon; M Cowan; C Edwards; V Fuster
Journal:  Circulation       Date:  1994-07       Impact factor: 29.690

6.  Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study.

Authors:  H D Lewis; J W Davis; D G Archibald; W E Steinke; T C Smitherman; J E Doherty; H W Schnaper; M M LeWinter; E Linares; J M Pouget; S C Sabharwal; E Chesler; H DeMots
Journal:  N Engl J Med       Date:  1983-08-18       Impact factor: 91.245

7.  Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group.

Authors: 
Journal:  Lancet       Date:  1996-03-02       Impact factor: 79.321

8.  Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. The RISC Group.

Authors: 
Journal:  Lancet       Date:  1990-10-06       Impact factor: 79.321

9.  Relation of severity of symptoms to transient myocardial ischemia and prognosis in unstable angina.

Authors:  R Bugiardini; A Borghi; A Pozzati; A Ruggeri; P Puddu; A Maseri
Journal:  J Am Coll Cardiol       Date:  1995-03-01       Impact factor: 24.094

10.  Predictors of non-Q-wave acute myocardial infarction in patients with acute ischemic syndromes: an analysis from the Thrombolysis in Myocardial Ischemia (TIMI) III trials.

Authors:  C P Cannon; B Thompson; C H McCabe; H S Mueller; J M Kirshenbaum; S Herson; J B Nasmith; B R Chaitman; E Braunwald
Journal:  Am J Cardiol       Date:  1995-05-15       Impact factor: 2.778

View more
  1 in total

1.  Pharmacodynamic characterization of the interaction between abciximab or tirofiban with unfractionated or a low molecular weight heparin in healthy subjects.

Authors:  U Klinkhardt; J Graff; D Westrup; C M Kirchmaier; H U Esslinger; H K Breddin; S Harder
Journal:  Br J Clin Pharmacol       Date:  2001-09       Impact factor: 4.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.